Emergent Biosolutions Inc (EBS) News

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced...

Form 8-K - Current report

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or...

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today...

Form 8-K - Current report

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) --  Emergent BioSolutions Inc. (NYSE: EBS) today announced...

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

For the second year, Emergent is teaming up with pro football legend, Emmitt Smith, to educate communities on...

Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced...

Form 8-K - Current report

Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals

GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced...

Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa

Active engagement with the World Health Organization, U.S. government and other global health leaders on...

Emergent BioSolutions Reports Second Quarter 2024 Financial Results

Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance rangeSecond Quarter 2024 Net...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country

Customer-focused approach and continued investments in NARCAN® Nasal Spray supply-readiness efforts help ensure...